Scale Development

Pierrel Research has got more than 20 years experience in the development, validation and analysis of :

• innovative health-related quality of life questionnaires
• unique disease-specific instrument to measure treatment effects or changes in disease status
• typical psychometric scales, disease-specific scales, questionnaires (e.g. symptom-related, HrQoL scales, QoL scales) and mixtures of these concepts as specified in the PRO guideline

Development usually is performed with the classical test theory (going back to Sir Edward Spearman).

Pierrel Research has been actively involved in many research projects in the indication of Alzheimer disease with international leading pharmaceutical companies and conducted essential registration studies.

Our history started when Pierrel Research contributed to the development of the first Alzheimer medication Tacrine®, supported its introduction into the market and designed the so called “Cognex management set”. Shortly after this first challenge, Pierrel Research, always concerned with the health, was deeply involved in the clinical trials and introduction into the market of Exelon® and, later on, of the innovative drug Memantine®, which was the first drug indicated for severe Alzheimer.

Nowadays and besides its participation in clinical trials, Pierrel Research has developed and validated a new scale to measure the efficacy of Alzheimer medication, ROSA® (Relevant Outcome Scale for Alzheimer’s disease).